1 / 24

MLAB 2401: Clinical Chemistry Keri Brophy-Martinez

MLAB 2401: Clinical Chemistry Keri Brophy-Martinez. Therapeutic Drug Monitoring. Therapeutic Drug Monitoring= TDM. Goal Ensure that a given drug dosage produces Maximal therapeutic benefit Minimal toxic adverse effects

aislin
Download Presentation

MLAB 2401: Clinical Chemistry Keri Brophy-Martinez

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. MLAB 2401: Clinical ChemistryKeri Brophy-Martinez Therapeutic Drug Monitoring

  2. Therapeutic Drug Monitoring= TDM • Goal • Ensure that a given drug dosage produces • Maximal therapeutic benefit • Minimal toxic adverse effects • Must have an appropriate concentration at site of action that produces benefits • Standard dosages derived from healthy population • Only the free fraction of drugs can interact with site of action, resulting in a biologic response

  3. Routes of Administration • Routes • Injections • Circulation= IV (intravenous) • Muscles=IM (intramuscular) • Skin= SC (subcutaneous) • Epidermal • Inhaled • Absorbed through skin • Rectal • Oral (most common)

  4. Pharmacokinetics • Involves the dynamics associated with the movement of drugs across cell membranes • Includes biological events: • Absorption • Distribution • Metabolism/Biotransformation • Excretion • Relationship of drug concentration to time • Process assists in establishing or modifying a dosage regimen

  5. Absorption • Rate at which drug leaves the site of administration and the extent to which this happens • Mechanism • Passive diffusion • Active transport

  6. Absorption: Limiting Factors • Oral Administration • Absorption depends on.. • Formulation of drug • liquid/pill • Intestinal motility • pH • Inflammation • Food • Presence of other drugs • Patient age • Pregnancy • Concurrent Pathologic Conditions

  7. Distribution • Dependent on • Blood flow • Capillary permeability • pH gradients • Lipid solubility of the drug • Binding of drugs to proteins/Availability of free fractions • Free vs. bound drug • Tissue volume

  8. Metabolism • Primarily occurs in the liver • Biotransformation of the parent drug molecule into one or more metabolites • Metabolites are: • water soluble • easily excreted by kidney or liver • Pharmacologically active or inactive

  9. First-Pass Metabolism

  10. Elimination • Elimination Routes • Hepatic metabolism • Renal filtration • Other: skin, lungs, mammary glands and salivary glands • Functional changes in organs can affect rate of elimination • i.e. : Hepatic disease with a loss of tissue result in slow rate of clearance with a longer half-life. • Elimination half-life • The time required to reduce the blood level concentration to one-half after equilibrium is obtained.

  11. Pharmacokinetics • Most drugs given on a scheduled basis not as a single bolus or mass • Oscillation between a maximum(peak) and a minimum (trough)of serum concentration • Goal of dosage regimens • Achieve troughs in therapeutic range and peaks that are non-toxic

  12. Sample Collection • Timing of TDM most important • Collaborate with nursing & phlebotomy staff for appropriate timing • Trough: right before next dose • Peak: one hour post administration of dose (Verify drug protocol) • Random • Specimen Type • Serum: no gel • Plasma: Heparinized • EDTA, Citrated, Oxalated not acceptable • Whole Blood • Saliva

  13. Drug Groups • Cardioactive • Antibiotics • Antiepileptic • Psychotherapeutic • Antiasthmatic • Immunosuppressive • Antineoplastic • Antihypertensive

  14. Drug Groups: Cardioactive • Digoxin • Used to treat CHF( congestive heart failure) • Peaks draw at 2 hours post dose • Inhibits sodium and potassium transport within the heart • Allows for better cardiac muscle contraction and rhythm • Lidocaine • Used to treat premature ventricular contractions • Affects the timing of cardiac contraction

  15. Drug Groups: Cardioactive (2) • Quinidine • Used to treat cardiac arrhythmic problems • Inhibits sodium and potassium channels • Prevents arrhythmias, atrial flutter and fibrillation • Procainamide • Used to treat cardiac arrhythmic situations • Blocks sodium channels • Affects cardiac muscle contraction • Often measured with NAPA(N-Acetyl procainamide)

  16. Drug Groups: Antibiotics • Aminoglycosides • Used to treat infections with gram-negative bacteria that are resistant to less toxic antibiotics • Inhibits protein synthesis of the micro-organism • Examples include: gentamycin, tobramycin, amikacin and kanamycin • Vancomycin • Used to treat infections with more-resistant gram-positive cocci and bacilli • Inhibits cell wall synthesis

  17. Drug Groups: Antiepileptics “AEDs” • Most first and second generation AEDs used to treat seizure disorders and epilepsy

  18. Drug Groups: Psychotherapeutic • Used to treat manic depression (bipolar disorder) • Lithium • Tricyclic Antidepressants “TCAs” • Clozapine

  19. Drug Group: Antiasthmatic • Used to treat neonatal breathing disorders or respiratory disoders of adults or children, like asthma • Examples include theophylline and theobromine

  20. Drug Group: Immunosuppressive • Monitoring of this group of drugs important to prevent organ rejection (host-versus-graft) • Used to treat autoimmune disease • Examples • Cyclosporine • Whole blood is the specimen of choice, since it sequesters in the RBC • Tacrolimus (Prograf) • Prevents rejection of liver and kidney transplants

  21. Drug Group: Antineoplastics • Inhibit RNA or DNA synthesis of tumor cells, leading to cell death • Methotrexate • Inhibits DNA synthesis

  22. Drug Group: Antihypertensive • Used in treatment of high blood pressure • Dilate blood vessels • Sodium nitroprusside • Used for short-term control of hypertension

  23. Techniques for Measurement of TDM • Immunoassays • Gas chromatography • Liquid chromatography • Mass spectrometry

  24. References • Arneson, W., & Brickell, J. (2007). Clinical Chemistry: A Laboratory Perspective . Philadelphia, PA: F.A. Davis Company. • Bishop, M., Fody, E., & Schoeff, l. (2010). Clinical Chemistry: Techniques, principles, Correlations. Baltimore: Wolters Kluwer Lippincott Williams & Wilkins. • Sunheimer, R., & Graves, L. (2010). Clinical Laboratory Chemistry. Upper Saddle River: Pearson .

More Related